Sponsor: 
Pfizer Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Quadrivalent meningococcal vaccines

Registered for use in people aged 12 months to 55 years.

MenACWY-TT — quadrivalent meningococcal (serogroups A, C, W-135, Y)–tetanus toxoid conjugate vaccine

Lyophilised powder in a monodose vial with separate pre-filled syringe or ampoule of solvent.

Each 0.5 mL reconstituted dose contains:

  • 5 µg meningococcal polysaccharide serogroup A
  • 5 µg meningococcal polysaccharide serogroup C
  • 5 µg meningococcal polysaccharide serogroup W-135
  • 5 µg meningococcal polysaccharide serogroup Y
  • 44 µg tetanus toxoid protein

May contain traces of:

  • trometamol
  • sucrose

The product information and consumer medicine information for Nimenrix have more details.

Audience: 
Infants and children
Previous

NeisVac-C

Next

Pneumovax 23

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018